Canaccord Genuity restated their buy rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note released on Wednesday, February 7th. Canaccord Genuity currently has a $522.00 price objective on the biopharmaceutical company’s stock.
“We are encouraged by better US Dupixent growth, but recognize that the pediatric atopic dermatitis market will be the core growth driver, with approval expected around 2021. Also, while we understand that REGN and investors are focusing more on Dupixent’s growth than EYLEA’s, the lack of EYLEA guidance going forward is concerning. REGN cannot give guidance on Dupixent since Sanofi books the revenues, and EYLEA is still expected to be the core revenue driver for REGN.”,” the firm’s analyst wrote.
A number of other equities analysts have also commented on REGN. BTIG Research restated a buy rating and set a $520.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, November 22nd. Jefferies Group reiterated a hold rating and issued a $421.00 price target on shares of Regeneron Pharmaceuticals in a research note on Friday, February 2nd. BMO Capital Markets set a $444.00 price target on Regeneron Pharmaceuticals and gave the company a hold rating in a research note on Monday, November 27th. JPMorgan Chase & Co. reiterated a hold rating on shares of Regeneron Pharmaceuticals in a research note on Monday, October 16th. Finally, Citigroup reiterated a buy rating and issued a $480.00 price target on shares of Regeneron Pharmaceuticals in a research note on Thursday, November 9th. Four research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eleven have assigned a buy rating to the stock. The stock currently has an average rating of Hold and a consensus price target of $463.19.
Regeneron Pharmaceuticals (NASDAQ:REGN) traded up $6.12 during trading hours on Wednesday, reaching $330.69. The company had a trading volume of 1,974,413 shares, compared to its average volume of 1,070,000. The firm has a market cap of $35,530.00, a PE ratio of 32.04, a P/E/G ratio of 1.39 and a beta of 1.47. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.18 and a current ratio of 3.82. Regeneron Pharmaceuticals has a 1-year low of $313.53 and a 1-year high of $543.55.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $5.23 EPS for the quarter, topping the Zacks’ consensus estimate of $4.18 by $1.05. Regeneron Pharmaceuticals had a return on equity of 28.48% and a net margin of 20.41%. The firm had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.50 billion. During the same quarter last year, the company earned $3.04 EPS. The company’s revenue was up 28.9% on a year-over-year basis. equities research analysts predict that Regeneron Pharmaceuticals will post 14.13 earnings per share for the current fiscal year.
In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $325.60, for a total transaction of $325,600.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 10.80% of the stock is currently owned by insiders.
Large investors have recently made changes to their positions in the company. Shell Asset Management Co. lifted its stake in shares of Regeneron Pharmaceuticals by 24.1% in the 3rd quarter. Shell Asset Management Co. now owns 15,435 shares of the biopharmaceutical company’s stock valued at $5,565,000 after purchasing an additional 2,999 shares during the period. DnB Asset Management AS acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $9,136,000. Northpointe Capital LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $2,089,000. Cubist Systematic Strategies LLC lifted its stake in shares of Regeneron Pharmaceuticals by 176.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 671 shares of the biopharmaceutical company’s stock valued at $330,000 after purchasing an additional 428 shares during the period. Finally, Griffin Asset Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $1,579,000. 65.89% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/15/canaccord-genuity-reaffirms-buy-rating-for-regeneron-pharmaceuticals-regn.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.